Allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 8-15

  Vyas, Paresh ^a   Appelbaum, Frederick R ^b   Craddock, Charles ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Acute myeloid leukemia; Conditioning regimen; Disease relapse; Graft versus leukemia; Leukemic stem progenitor cell; Reduced intensity conditioning

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; DISEASE ERADICATION; GENETIC MARKER; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA CELL; LEUKEMIA RELAPSE; PROPHYLAXIS; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL; TREATMENT FAILURE; ADULT; ALLOTRANSPLANTATION; CANCER STEM CELL; CHROMOSOME ABERRATION; DISEASE MANAGEMENT; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, MYELOID, ACUTE; MORTALITY; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; SURVIVAL;

MYELOABLATIVE AGENT;

ADULT; CHROMOSOME ABERRATIONS; DISEASE MANAGEMENT; DRUG RESISTANCE, NEOPLASM; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELOABLATIVE AGONISTS; NEOPLASTIC STEM CELLS; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 84927125987     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.10.026     Document Type: Review

References (86)

1. Burnett A., Wetzler M., Lowenberg B. Therapeutic advances in acute myeloid leukemia. JClin Oncol 2011, 29:487-494.
2. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-574.
3. Burnett A.K., Russell N.H., Hills R.K., et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. JClin Oncol 2012, 30:3924-3931.
4. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. JClin Oncol 2006, 24:3904-3911.
5. Cairoli R., Beghini A., Grillo G., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006, 107:3463-3468.
6. Gaidzik V.I., Bullinger L., Schlenk R.F., et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. JClin Oncol 2011, 29:1364-1372.
7. Mendler J.H., Maharry K., Radmacher M.D., et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. JClin Oncol 2012, 30:3109-3118.
8. Metzeler K.H., Maharry K., Radmacher M.D., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. JClin Oncol 2011, 29:1373-1381.
9. Gaidzik V.I., Paschka P., Spath D., et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. JClin Oncol 2012, 30:1350-1357.
10. Cornelissen J.J., Gratwohl A., Schlenk R.F., et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012, 9:579-590.
11. Cancer Genome Atlas Research N Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. NEngl J Med 2013, 368:2059-2074.
12. Supek F., Minana B., Valcarcel J., et al. Synonymous mutations frequently act as driver mutations in human cancers. Cell 2014, 156:1324-1335.
13. Groschel S., Sanders M.A., Hoogenboezem R., et al. Asingle oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 2014, 157:369-381.
14. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. NEngl J Med 2012, 366:1079-1089.
15. Hughes A.E., Magrini V., Demeter R., et al. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet 2014, 10:e1004462.
16. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
17. Kronke J., Bullinger L., Teleanu V., et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013, 122:100-108.
18. Goardon N., Marchi E., Atzberger A., et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011, 19:138-152.
19. Ishikawa F., Yoshida S., Saito Y., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007, 25:1315-1321.
20. Klco J.M., Spencer D.H., Miller C.A., et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014, 25:379-392.
21. van Rhenen A., Feller N., Kelder A., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11:6520-6527.
22. van Rhenen A., Moshaver B., Kelder A., et al. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007, 21:1700-1707.
23. Gerber J.M., Smith B.D., Ngwang B., et al. Aclinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012, 119:3571-3577.
24. Craddock C., Quek L., Goardon N., et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 2013, 27:1028-1036.
25. Gentles A.J., Plevritis S.K., Majeti R., Alizadeh A.A. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010, 304:2706-2715.
26. Eppert K., Takenaka K., Lechman E.R., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011, 17:1086-1093.
27. Jan M., Snyder T.M., Corces-Zimmerman M.R., et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012, 4:149ra18.
28. Corces-Zimmerman M.R., Hong W.J., Weissman I.L., et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014, 111:2548-2553.
29. Shlush L.I., Zandi S., Mitchell A., et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014, 506:328-333.
30. Woll P.S., Kjallquist U., Chowdhury O., et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells invivo. Cancer Cell 2014, 25:794-808.
31. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990, 76:1867-1871.
32. Appelbaum F.R. Dose intensity of preparative regimens for acute myeloid leukemia - one-size-fits-all or tailor-made?. Best Pract Res ClinHematol 2010, 23:509-517.
33. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
34. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865-872.
35. Martino R., de Wreede L., Fiocco M., et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant 2013, 48:761-770.
36. Chen Y.B., Coughlin E., Kennedy K.F., et al. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant 2013, 19:981-987.
37. Bornhauser M., Kienast J., Trenschel R., et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3trial. Lancet Oncol 2012, 13:1035-1044.
38. Alyea E.P., Kim H.T., Ho V., et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006, 12:1047-1055.
39. Weissinger F., Sandmaier B.M., Maloney D.G., et al. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001, 98:3584-3588.
40. Fukuda T., Hackman R.C., Guthrie K.A., et al. Risks and outcomes ofidiopathic pneumonia syndrome after nonmyeloablative andconventionalconditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003, 102:2777-2785.
41. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002, 8:512-520.
42. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
43. Blaise D., Tabrizi R., Boher J.M., et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer 2013, 119:602-611.
44. Blaise D., Castagna L. Do different conditioning regimens really make a difference?. Hematology Am Soc Hematol Educ Program 2012, 2012:237-245.
45. Appelbaum F.R., Bacigalupo A., Soiffer R. Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation-a debate. Biol Blood Marrow Transplant 2012, 18:S111-115.
46. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
47. Pasquini M.C., Devine S., Mendizabal A., et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 2012, 30:3194-3201.
48. Parimon T., Au D.H., Martin P.J., Chien J.W. Arisk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006, 144:407-414.
49. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
50. Sorror M.L., Storb R.F., Sandmaier B.M., et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. JClin Oncol 2014, 32:3249-3256.
51. McCune J.S., Batchelder A., Guthrie K.A., et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther 2009, 85:615-622.
52. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
53. Petersdorf E.W., Malkki M., Gooley T.A., et al. MHC-resident variation affects risks after unrelated donor hematopoietic cell transplantation. Sci Transl Med 2012, 4:144ra01.
54. Sorror M.L., Appelbaum F.R. Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. Expert Rev Hematol 2013, 6:547-562.
55. Ciurea S.O., Andersson B.S. Busulfan in hematopoietic stem celltransplantation. Biol Blood Marrow Transplant 2009, 15:523-536.
56. Bredeson C.N., Zhang M.J., Agovi M.A., et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:993-1003.
57. Lee J.H., Joo Y.D., Kim H., et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. JClin Oncol 2013, 31:701-709.
58. Gyurkocza B., Gutman J., Nemecek E.R., et al. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant 2014, 20:549-555.
59. Pagel J.M., Gooley T.A., Rajendran J., et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plusfludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009, 114:5444-5453.
60. Appelbaum F.R. Optimising the conditioning regimen for acutemyeloidleukaemia. Best Pract Res Clin Hematol 2009, 22:543-550.
61. Schmid C., Labopin M., Nagler A., et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012, 119:1599-1606.
62. Bejanyan N., Oran B., Shanley R., et al. Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord bloodtransplantation. Bone Marrow Transplant 2014, 49:1029-1035.
63. Craddock C., Labopin M., Pillai S., et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011, 25:808-813.
64. Walter R.B., Sandmaier B.M., Storer B.E., et al. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for AML in first morphological remission. Biol BloodMarrow Transplant 2014, [Epub ahead of print]. 10.1016/j.bbmt.2014.09.022.
65. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. JClin Oncol 2011, 29:1190-1197.
66. Bejar R., Stevenson K.E., Caughey B., et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. JClin Oncol 2014, 32:2691-2698.
67. Sobecks R.M., Rybicki L., Yurch M., et al. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS. Bone Marrow Transplant 2012, 47:633-638.
68. Schmid C., Schleuning M., Ledderose G., et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. JClin Oncol 2005, 23:5675-5687.
69. Schmid C., Schleuning M., Schwerdtfeger R., et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006, 108:1092-1099.
70. Bertz H., Potthoff K., Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. JClin Oncol 2003, 21:1480-1484.
71. Chevallier P., Labopin M., Socie G., et al. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. Haematologica 2014, 99:1486-1491.
72. Mawad R., Gooley T.A., Rajendran J.G., et al. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant 2014, 20:1363-1368.
73. Bacigalupo A., Vitale V., Corvo R., et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000, 108:99-104.
74. Baron F., Labopin M., Niederwieser D., et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012, 26:2462-2468.
75. Craddock C., Nagra S., Peniket A., et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010, 95:989-995.
76. Olavarria E., Siddique S., Griffiths M.J., et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007, 110:4614-4617.
77. Platzbecker U., Wermke M., Radke J., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012, 26:381-389.
78. Goodyear O., Agathanggelou A., Novitzky-Basso I., et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010, 116:1908-1918.
79. Choi J., Ritchey J., Prior J.L., et al. Invivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010, 116:129-139.
80. Schroeder T., Frobel J., Cadeddu R.P., et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia 2013, 27:1910-1913.
81. Goodyear O.C., Dennis M., Jilani N.Y., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119:3361-3369.
82. Mohty M., Chevallier P. Azacitidine after allo-SCT: the good without the bad?. Blood 2012, 119:3199-3200.
83. Sockel K., Bornhaeuser M., Mischak-Weissinger E., et al. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. Haematologica 2012, 97:e34-e35.
84. Christopeit M., Kuss O., Finke J., et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. JClin Oncol 2013, 31:3259-3271.
85. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. JClin Oncol 2007, 25:4938-4945.
86. Schroeder T., Czibere A., Platzbecker U., et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013, 27:1229-1235.